Article

State of glaucoma therapy focus of keynote

This could be a banner year for breakthroughs in glaucoma care. New understanding of the central nervous system and the nature of glaucoma has advanced researchers to the verge of changing the standard of care in this leading cause of blindness. “We are not talking about an eye disease any more when we talk about glaucoma,” said Louis B. Cantor, MD, chairman and professor of ophthalmology and director of glaucoma service at Indiana University, Indianapolis. “We are talking about a central nervous system disorder. We are redefining the optic nerve. I am very excited about new concepts in neuroprotection.”

San Francisco-This could be a banner year for breakthroughs in glaucoma care. New understanding of the central nervous system and the nature of glaucoma has advanced researchers to the verge of changing the standard of care in this leading cause of blindness.
    
“We are not talking about an eye disease any more when we talk about glaucoma,” said Louis B. Cantor, MD, chairman and professor of ophthalmology and director of glaucoma service at Indiana University, Indianapolis. “We are talking about a central nervous system disorder. We are redefining the optic nerve. I am very excited about new concepts in neuroprotection.”
    
Dr. Cantor delivered the opening keynote address at the Glaucoma 360 New Horizons Forum on Friday. Current glaucoma treatment is still about controlling IOP, but care is on the verge of emphasizing earlier, more aggressive management to reduce and delay progression.
    
Clinicians are coming to appreciate the reality that glaucoma is a multifactorial disease. Though treating IOP helps to some degree, there is a growing understanding that protecting the retinal ganglia is a key clinical goal. New treatments will come from a growing understanding of the pathophysiology of glaucoma as well as a new understanding of the structures and mechanisms at the neural-retinal rim and new clinical targets.
     
“We are on the cusp of redefining the optic nerve and assessing the structural damage of glaucoma,” he said. “We are on the cusp of offering our patients an alternative to the torture of visual field.”

New techniques are already suggesting ways the assessment of glaucoma is about to change. Four-channel multifocal VEP offers synchronized signal acquisition. Minimally invasive glaucoma surgical procedures continue to move toward clinical use. Suprachoroidal microstents, subconjunctival microstents, and laser trabeculectomy all offer improvements over conventional surgical interventions.
    
“Not every patients needs a hole in the eye,” Dr. Cantor said. “This year could be our lucky 13. We have many developments on the horizon.”

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.